SEARCH

SEARCH BY CITATION

References

  • 1
    Elsner J, Forssmann U. Another renaissance of eosinophils in allergic diseases. ACI Int 2002;14: 151155.
  • 2
    Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79: 31013109.
  • 3
    Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995;182: 11691174.
  • 4
    Warringa RA, Mengelers HJ, Kuijper PH, Raaijmakers JA, Bruijnzeel PL, Koenderman L. In vivo priming of platelet-activating factor-induced eosinophil chemotaxis in allergic asthmatic individuals. Blood 1992;79: 18361841.
  • 5
    Uings I, McKinnon M. Development of IL-5 receptor antagonists. Curr Pharm Des 2002;8: 18371844.
  • 6
    Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356: 21442148.
  • 7
    Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167: 199204.
  • 8
    Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003;21: 799803.
  • 9
    Leiferman KM. A role for eosinophils in atopic dermatitis. J Am Acad Dermatol 2001;45(1 Suppl.):S21S24.
  • 10
    Wedi B, Raap U, Lewrick H, Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997;100: 536543.
  • 11
    Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92: 4447.
  • 12
    Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195: 1019.
  • 13
    Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001;107: 535541.
  • 14
    Hijnen D, Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004;113: 334340.
  • 15
    Beck LA, Dalke S, Leiferman KM, Bickel CA, Hamilton R, Rosen H et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects. J Immunol 1997;159: 29622972.
  • 16
    Rothenberg ME. Eosinophilia. N Engl J Med 1998;338: 15921600.
  • 17
    Kay AB, Menzies-Gow A. Eosinophils and interleukin-5: the debate continues. Am J Respir Crit Care Med 2003;167: 15861587.